Not an actual patient.
How it works
An innovative approach to hemophilia treatment
HYMPAVZI works to help achieve hemostasis through rebalancing.
One way to increase clotting function is to replace the procoagulants, i.e., the missing clotting function factors VIII and IX.
Rebalancing therapies instead target anticoagulants. One of the anticoagulants that prevents clotting is called tissue factor pathway inhibitor (TFPI).
HYMPAVZI works by blocking TFPI
This helps to restore hemostasis.
Factor VIII or IX deficiency causes an imbalance (leading to bleeding).
HYMPAVZI inhibits an anticoagulant in order to help increase clotting. This is how rebalancing works.
Because HYMPAVZI works in an innovative way to block TFPI instead of replacing factor, it works independent of factor VIII or factor IX levels.
See the clinical trial design